Turning Point Therapeutics, Inc.
(NASDAQ GS: TPTX)
Rigrodsky Law, P.A. is investigating Turning Point Therapeutics, Inc. (“Turning Point”) regarding possible breaches of fiduciary duties and other violations of law related to Turning Point’s agreement to be acquired by Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the agreement Turning Point’s shareholders will receive $76.00 in cash for each share of Turning Point common stock they own.